
EU Rejects Lilly’s Alzheimer’s Drug Kisunla, Following Same Path as Rival Leqembi
Eli Lilly’s Alzheimer’s drug Kisunla has received a negative opinion from the European Union’s drug evaluation board. Meanwhile, competitors Biogen and Eisai are still fighting for market access for rival med Leqembi. The EU’s Committee for Medicinal …